Applied DNA Sciences CEO acquires 18,691 shares at $0

Applied DNA Sciences reported an insider equity change.

Rhea-AI Filing Summary

Applied DNA Sciences reported an insider equity change. The Chief Executive Officer filed a Form 4 showing acquisition of 18,691 shares of common stock on 10/17/2025 at a price of $0, coded “A.” Following the transaction, the officer beneficially owned 18,695 shares, held directly.

The filing notes that 100% of the related restricted stock units vest 90 days from the date of grant.

Insider Trade Summary

Grant/Award: 18,691 shares

Grant/Award 1 txn

Insider Shorrock Clay

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	18,691	$0.00	$0.00

Holdings After Transaction: Common Stock — 18,695 shares (Direct)

Footnotes (1)

1. F1. 100% of the restricted stock units vest upon 90 days from the date of grant

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did APDN disclose in this Form 4?

The CEO acquired 18,691 shares of common stock on 10/17/2025 at $0, coded “A,” and now holds 18,695 shares directly.

Who is the reporting person in APDN’s Form 4?

An Officer of the company, serving as Chief Executive Officer.

What does the transaction code 'A' mean for APDN’s Form 4?

It indicates an acquisition of securities, recorded at a price of $0 for the common stock reported.

How many APDN shares are beneficially owned after the transaction?

The reporting person beneficially owns 18,695 shares following the reported transaction.

What is the vesting detail mentioned for APDN?

The filing states that 100% of the restricted stock units vest 90 days from the date of grant.

What is the security reported for APDN in this filing?

Common Stock was reported in Table I; no derivative securities were listed in Table II.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/20/2025 - 04:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shorrock Clay

(Last) (First) (Middle)

50 HEALTH SCIENCES DRIVE

(Street)

STONY BROOK NY 11790

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
APPLIED DNA SCIENCES INC [ BNBX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	10/17/2025		A		18,691	A	$0	18,695	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. 100% of the restricted stock units vest upon 90 days from the date of grant

	/s/ Beth Jantzen, Attorney-in-Fact	10/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.